Search clinical trials for: HCP1903

Total 73 results

Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1903

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate the PK, Safety and Tolerability of HCP1803.

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia

Primary Hypercholesterolemia

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1801 in Healthy Subjects

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Not yet recruiting

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules

Benign Prostatic Hyperplasia
Hanmi Pharmaceutical Company Limited

Completed

A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects.

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

PK and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 Under Fed Condition in Healthy Male Volunteers

Prostatic Hyperplasia | Erectile Dysfunction
Hanmi Pharmaceutical Company Limited

Completed

Pharmacokinetics and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 in Healthy Male Volunteers

Prostatic Hyperplasia | Erectile Dysfunction

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate the Pharmacokinetics and Safety Between HCP1902 and Co-administration of RLD2007, RLD2008

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension (HM_APOLLO)

Hypertension

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination of HCP1904 and Co-Administration of RLD2001-2 and RLD2006 Tablets in Healthy Subjects.

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia

Primary Hypercholesterolemia

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Trial to Evaluate the Efficacy and Safety of HCP1302

Hypertension | Erectile Dysfunction
Hanmi Pharmaceutical Company Limited

Unknown

Clinical Efficacy and Safety Evaluation of HCP1202 in COPD Patients

Chronic Obstructive Pulmonary Disease
Hanmi Pharmaceutical Company Limited

Completed

Single-dose, 2-way Crossover Open Study to Evaluate the Food Effect on the PK of HCP1201 in Healthy Volunteers

Diabetes Mellitus

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension (HM_APOLLO)

Hypertension

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Not yet recruiting

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Pharmacokinetics and Safety of HCP1105 and Co-administration of HGP0918, HGP0816 in Healthy Male Volunteers

Hyperlipidemias

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Efficacy and Safety of HCP1102 Capsule

Asthma With Allergic Rhinitis

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Not yet recruiting

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Pharmacokinetics of HCP1305 and Co-administration of HCP0605, HGP0816 in Healthy Male Volunteers

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers

Primary Hypercholesterolemia
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Active, not recruiting

Administration of Donor T Cells With the Caspase-9 Suicide Gene (DOTTI)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Non Hodgkin Lymphoma | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia | Hemophagocytic Lymphohistiocytosis | Epstein Barr Virus Infection | X-linked Lymphoproliferative Disease | Hemophagocytic Syndrome | Familial Hemophagocytic Lymphohistiocytosis

United States
Hanmi Pharmaceutical Company Limited

Completed

Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers

Overactive Bladder
Hanmi Pharmaceutical Company Limited

Completed

Pharmacokinetics of HCP1401 and Co-administration of HCP0605, HGP1405 in Healthy Male Volunteers

Healthy

Korea, Republic of
Bellicum Pharmaceuticals

No longer available

BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study

Hurler Syndrome | Inborn Errors of Metabolism | Metachromatic Leukodystrophy | Inherited Metabolic Disorder | Lysosomal Storage Disorder

United States
Hanmi Pharmaceutical Company Limited

Unknown

Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD

Hyperlipidemias

Korea, Republic of
Bellicum Pharmaceuticals

Withdrawn

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

Hematologic Malignancies

United States
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate the Pharmacokinetics and Safety of HCP1704 in Healthy Subjects

Health, Subjective

Korea, Republic of
Bellicum Pharmaceuticals

Terminated

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Uveal Melanoma

United States
Bellicum Pharmaceuticals

Suspended

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Bellicum Pharmaceuticals

Active, not recruiting

Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Hematologic Neoplasms | Multiple Myeloma

United States
Bellicum Pharmaceuticals

Terminated

Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

Lymphoma, Non-Hodgkin | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Primary Immunodeficiency | Anemia, Sickle Cell | Hemoglobinopathies | Fanconi Anemia | Anemia, Aplastic | Thalassemia | Cytopenia | Diamond Blackfan Anemia | Leukemia, Acute Myeloid (AML), Child

Italy
Bellicum Pharmaceuticals

Withdrawn

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Myelodysplastic Syndromes | Leukemia | Multiple Myeloma | Lymphomas | Other High-risk Hematological Malignancies
Hanmi Pharmaceutical Company Limited

Completed

Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients

Hypertension

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients

Hypertension

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients

Hypertension

Korea, Republic of
Bellicum Pharmaceuticals

Active, not recruiting

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Hematologic Malignancy

Italy
Bellicum Pharmaceuticals

Active, not recruiting

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Lymphoma, Non-Hodgkin | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Anemia, Aplastic | Primary Immune Deficiency Disorder | Cytopenia | Osteopetrosis | Leukemia, Acute Myeloid (AML), Child | Hemoglobinopathy in Children

United States
Hanmi Pharmaceutical Company Limited

Completed

Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis

Perennial Allergic Rhinitis

Korea, Republic of
Bellicum Pharmaceuticals

Completed

Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer

Castrate Resistent Prostate Cancer

United States
Bellicum Pharmaceuticals
M.D. Anderson Cancer Center; The University of Texas Health Science Center,... and other collaborators

Completed

MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

Castrate Resistant Prostate Cancer (CRPC)

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Bellicum Pharmaceuticals

Withdrawn

Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Myelodysplastic... and other conditions

United States
Bellicum Pharmaceuticals

Terminated

Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant

Lymphoma, Non-Hodgkin | Acute Lymphoblastic Leukemia | Primary Immunodeficiency | Anemia, Sickle Cell | Hemoglobinopathies | Fanconi Anemia | Anemia, Aplastic | Myelodysplastic Syndrome | Thalassemia | Cytopenia | Diamond Blackfan Anemia | Osteopetrosis | Leukemia, Acute Myeloid (AML), Child

United Kingdom, Italy
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions Between HGP0904, HGP0608, and HCP1306 in Healthy Male Subjects.

Healthy

Korea, Republic of
Centre Hospitalier Universitaire de Besancon
Etablissement Français du Sang; Bellicum Pharmaceuticals

Unknown

T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. (Side_by_Cide)

Hematological Malignancies | Graft Versus Host Disease

France
Bellicum Pharmaceuticals

Active, not recruiting

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia

United States
Yuhan Corporation
Chonbuk National University Hospital

Completed

Clinical Trial to Evaluate the Safety and Pharmacokinetics of YHP1903 in Healthy Volunteers

Healthy Volunteer

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Evaluating the Bioequivalence of HIP1403, HGP0919

Healthy

Korea, Republic of

Search clinical trials for: HCP1903

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations